Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Roberts

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Hepatology (Baltimore, Md.)|October 6, 2015
Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is neededThai P Hong, Paul Gow, Michael Fink, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Nature Communications|August 30, 2025
Trait mediation explains decadal distributional shifts for a wide range of insect taxaYoann Bourhis, Alice E Milne, Chris R Shortall, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Nature Communications|October 1, 2025
Author Correction: Trait mediation explains decadal distributional shifts for a wide range of insect taxaYoann Bourhis, Alice E Milne, Chris R Shortall, et al.
Scandinavian Journal of Gastroenterology|May 11, 2016
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world studyAdam Doyle, Philip Marsh, Raghubinder Gill, et al.
Hepatology (Baltimore, Md.)|March 6, 2009
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapySilvana Gaudieri, Andri Rauch, Katja Pfafferott, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Hepatology (Baltimore, Md.)|October 6, 2015
Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is neededThai P Hong, Paul Gow, Michael Fink, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Nature Communications|August 30, 2025
Trait mediation explains decadal distributional shifts for a wide range of insect taxaYoann Bourhis, Alice E Milne, Chris R Shortall, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Nature Communications|October 1, 2025
Author Correction: Trait mediation explains decadal distributional shifts for a wide range of insect taxaYoann Bourhis, Alice E Milne, Chris R Shortall, et al.
Scandinavian Journal of Gastroenterology|May 11, 2016
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world studyAdam Doyle, Philip Marsh, Raghubinder Gill, et al.
Hepatology (Baltimore, Md.)|March 6, 2009
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapySilvana Gaudieri, Andri Rauch, Katja Pfafferott, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.
Pageof 7